More Than Ever, Diversity and Inclusion Matter at Eli Lilly and Company
Lilly’s Dave Ricks is passionate about diversity and inclusion at a crucial time.
Lilly’s Dave Ricks is passionate about diversity and inclusion at a crucial time.
Digital tools allow biopharma firms to interact with physicians and patients in new ways, leading to new business models and better outcomes.
The medical aesthetics market will rebound, but it will be different than it was before. Players and investors must start envisioning—and planning for—their future now.
As countries begin to lift restrictions on social interaction, effective deployment of contact tracing will be a critical weapon in the battle to contain COVID-19. But it won’t succeed without privacy safeguards and the right incentives for adoption.
A new consumer sentiment survey reveals concrete steps that health care providers can take to accelerate patients’ return.
There are positive signs of potential benefits across multiple drug classes and candidates.
What happens when longstanding channels of interaction no longer function? Companies are fundamentally changing the way they support the delivery of health care.
Preparing Localities for Action Against Novel Coronavirus (PLAN) is a scenario-planning tool that identifies potential US supply and demand imbalances down to the county level.
In their response to COVID-19, pharma and medtech companies have been true to their purpose. They now face questions that go beyond addressing the virus itself.
A new global survey reveals patient priorities around engagement, innovation and impact, and how pharma companies can benefit by becoming more patient centric.
BCG has taken a look at how biopharma can succeed in the next decade, and we’ve identified five major business imperatives.
Quantum computing has the potential to significantly accelerate, enhance the quality of, and reduce the costs of drug discovery.
An advanced algorithm helps doctors identify patients at risk of developing a serious kidney complication, enabling hospitals to lower treatment costs and save lives.
When biopharma companies apply data and analytics, they can make smarter commercial decisions, get better treatment information to physicians, and help save lives.
A recent analysis shows disturbing variations in the use of a key diagnostic for lung cancer patients. Adopting new protocols and tools can lead to better care.
Launching an orphan treatment is more complicated than ever. Here’s how to successfully navigate the challenges.
Given the growing complexity of customers’ needs and other sales challenges, pharma companies should activate six sales force roles.
“Double down on your loyalists”—and other insights to improve sales team efficiency.
Although women make up the majority of health care employees, men still dominate the corner office. Here are six ways to give women a fair shot at the top.
Pockets of opportunity await generic-drug companies that are prepared to adopt new strategies.
BCG’s 2019 benchmark study found that companies need to relentlessly manage the elements that demand the greatest spending—internal and contract manufacturing.
Even highly regulated and rigid industries can benefit from new ways of working.
Agile can help pharma companies deal with an intractable obstacle.
The Indian pharmaceutical sector has faced significant disruptions across its value chain, including the quality function, due to Covid-19. For most pharmaceutical companies, the quality function has been plagued by several. This perspective is an analysis of these measures and their impact across the pharmaceutical companies including four key learnings for the quality function.
Machine learning can make it much easier to determine the probability of a startup’s success.
New technologies are transforming the pharmaceutical industry’s approach to R&D. What’s happening now in the field—and what’s coming next?
These new therapies are poised to revolutionize oncology. It all depends on reaching a larger patient base and simplifying manufacturing and the supply chain.
These curative treatments are often unique. They face a very different type of marketplace.
